• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Acadia’s schizophrenia drug trial fails to meet primary endpoint

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 12, 2024 at 11:43: AM
via US-based biopharmaceutical company Acadia Pharmaceuticals has reported that its Phase III ADVANCE-2 clinical trial of pimavanserin for the treatment of negative symptoms of schizophrenia did not meet its primary endpoint.

article source
 




Top Bottom
Back
Quote